Citations

Clear

12 citation(s) found for "Schaik, Ron HN van".

Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Lemaı̂tre, F. , Barten, Markus J. , Bergan, Stein , Shipkova, Maria , Vinks, Sander, Wieland, Eberhard , Bornemann-Kolatzki, Kirsten , Brunet, Mercè , Winter, Brenda C. M. de , Ito, Taihei, Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lawson, Roland , Lloberas, Núria , Marquet, Pierre , Millán, Olga , Mizuno, Tomoyuki , Noceti, Ofelia , Oellerich, Michael , Pattanaik, Smita , Seger, Christoph , Schaik, Ron HN van , Venkataramanan, Raman , Walson, Phil, Woillard, Jean‐Baptiste , Langman, Loralie J., Masuda, Satohiro , Lemaitre, Florian, Gelder, Teun van , Vinks, Sander, Dieterlen, Maja‐Theresa , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Walson, Philip D.

Mayo Clinic

Therapeutic Drug Monitoring | September 27, 2024 | Volume: 47 | Issue: 1 | Pages: 4-31

10.1097/ftd.0000000000001250 | PMID 39331837 Get It

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long‐Term Mortality Risk
Bakker, Marie de , Scholte, Niels T B , Oemrawsingh, Rohit M. , Umans, Victor A. , Kietselaer, Bas , Schotborgh, Carl E. , Ronner, Eelko , Lenderink, Timo , Aksoy, Ismail , Harst, Pim van der , Asselbergs, Folkert W. , Maas, Arthur , Ophuis, Anton J. Oude, Krenning, Boudewijn J., Winter, Robbert J. de , The, Salem H.K., Wardeh, Alexander J. , Hermans, Walter, Cramer, G. Etienne , Schaik, Ron HN van , Akkerhuis, K. Martijn , Kardys, Isabella , Boersma, Eric , Gasthuis, Franciscus, de Bakker, Marie , Schotborgh, Carl , van der Harst, Pim , de Winter, Robbert J , Schaik, Ron H. N. van , de Rijke, Yolanda B , Kardys, Isabella , Boersma, Eric , Lenderink, Timo , Kietselaer, Bas L J H

Mayo Clinic

Journal of the American Heart Association | January 12, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.1161/jaha.123.031646 | PMID 38214281 Get It

Background We aimed to identify patients with subphenotypes of postacute coronary syndrome (ACS) using repeated measurements of high‐sensitivity cardiac troponin T, N‐terminal pro‐B‐type natriuretic peptide, high‐sensitivity C‐reactive protein, and growth differentiation factor 15 in the year after the index admission, and to investigate their association with long‐term mortality risk. Methods and Results BIOMArCS (BIOMarker Study to Identify the Acute Risk of a Coronary Syndrome) was an observational study of patients with ACS, who underwent high‐frequency blood sampling for 1 year. Biomarkers were measured in a median of 16 repeated samples per individual. Cluster analysis was performed to identify biomarker‐based subphenotypes in 723 patients without a repeat ACS in the first year. Patients with a repeat ACS (N=36) were considered a separate cluster. Differences in all‐cause death were evaluated using accelerated failure time models (median follow‐up, 9.1 years; 141 deaths). Three biomarker‐based clusters were identified: cluster 1 showed low and stable biomarker concentrations, cluster 2 had elevated concentrations that subsequently decreased, and cluster 3 showed persistently elevated concentrations. The temporal biomarker patterns of patients in cluster 3 were similar to those with a repeat ACS during the first year. Clusters 1 and 2 had a similar and favorable long‐term mortality risk. Cluster 3 had the highest mortality risk. The adjusted survival time ratio was 0.64 (95% CI, 0.44–0.93; P =0.018) compared with cluster 1, and 0.71 (95% CI, 0.39–1.32; P =0.281) compared with patients with a repeat ACS. Conclusions Patients with subphenotypes of post‐ACS with different all‐cause mortality risks during long‐term follow‐up can be identified on the basis of repeatedly measured cardiovascular biomarkers. Patients with persistently elevated biomarkers have the worst outcomes, regardless of whether they experienced a repeat ACS in the first year.
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs
Nijenhuis, Marga , Manson, Lisanne E. N. , Soree, Bianca, Boer-Veger, Nienke de, Buunk, Anne M. , Houwink, Elisa J. F. , Risselada, Arne, Rongen, Gerard A. , Schaik, Ron HN van , Swen, Jesse J. , Westrhenen, Roos van , Deneer, Vera H.M. , Houwink, Elisa J F , Boer‐Veger, Nienke J. de, Touw, Daan Johannes , Guchelaar, Henk‐Jan

Mayo Clinic

No container title available | November 8, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3255043/v1 Get It

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the gene-drug interaction of CYP2C9 and HLA-B with phenytoin, HLA-A and HLA-B with carbamazepine and HLA-B with oxcarbazepine and lamotrigine. A systematic review was performed and pharmacotherapeutic recommendations were developed. For CYP2C9 intermediate and poor metabolisers, the DPWG recommends lowering the daily dose of phenytoin and adjust based on effect and serum concentration after 7–10 days. For HLA-B*15:02 carriers, the risk of severe cutaneous adverse events associated with phenytoin, carbamazepine, oxcarbazepine and lamotrigine is strongly increased. For carbamazepine, this risk is also increased in HLA-B*15:11 and HLA-A*31:01 carriers. For HLA-B*15:02, HLA-B*15:11 and HLA-A*31:01 positive patients, the DPWG recommends choosing an alternative anti-epileptic drug. If not possible, it is recommended to advise the patient to report any rash while using carbamazepine, lamotrigine, oxcarbazepine or phenytoin immediately. Carbamazepine should not be used in an HLA-B*15:02 positive patient. DPWG considers CYP2C9 genotyping before the start of phenytoin “essential” for toxicity prevention. For patients with an ancestry in which the abovementioned HLA-alleles are prevalent, the DPWG considers HLA-B*15:02 genotyping before the start of carbamazepine, phenytoin, oxcarbazepine and lamotrigine “beneficial”, as well as genotyping for HLA-B*15:11 and HLA-A*31:01 before initiating carbamazepine.
Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort
Gürgöze, Muhammed T. , Akkerhuis, K. Martijn , Umans, Victor A. , Kietselaer, Bas , Schotborgh, Carl E. , Lenderink, Timo , Aksoy, Ismail , Harst, Pim van der , Asselbergs, Folkert W. , Maas, Arthur , Ophuis, Anton J. Oude, Krenning, Boudewijn J., Winter, Robbert J. de , The, Salem H.K., Wardeh, Alexander J. , Hermans, Walter, Cramer, G. Etienne , Gorp, Ina van, Schaik, Ron H. N. van , Boersma, Eric , Lenderink, Timo , Boersma, Eric , van der Harst, Pim , Kietselaer, Bas L J H , Oemrawsingh, Rohit M. , Ronner, Eelko , de Rijke, Yolanda B

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | April 25, 2023 | Volume: 12 | Issue: 7 | Pages: 451-461

10.1093/ehjacc/zuad042 | PMID 37096818 Get It

Abstract Aims Evidence regarding the role of serial measurements of biomarkers for risk assessment in post-acute coronary syndrome (ACS) patients is limited. The aim was to explore the prognostic value of four, serially measured biomarkers in a large, real-world cohort of post-ACS patients. Methods and results BIOMArCS is a prospective, multi-centre, observational study in 844 post-ACS patients in whom 12 218 blood samples (median 17 per patient) were obtained during 1-year follow-up. The longitudinal patterns of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and growth differentiation factor 15 (GDF-15) were analysed in relation to the primary endpoint (PE) of cardiovascular mortality and recurrent ACS using multivariable joint models. Median age was 63 years, 78% were men and the PE was reached by 45 patients. The average biomarker levels were systematically higher in PE compared with PE-free patients. After adjustment for 6-month post-discharge Global Registry of Acute Coronary Events score, 1 standard deviation increase in log[hs-cTnT] was associated with a 61% increased risk of the PE [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.02–2.44, P = 0.045], while for log[GDF-15] this was 81% (HR 1.81, 95% CI 1.28–2.70, P = 0.001). These associations remained significant after multivariable adjustment, while NT-proBNP and hs-CRP were not. Furthermore, GDF-15 level showed an increasing trend prior to the PE (Structured Graphical Abstract). Conclusion Longitudinally measured hs-cTnT and GDF-15 concentrations provide prognostic value in the risk assessment of clinically stabilized patients post-ACS. Clinical Trial Registration The Netherlands Trial Register. Currently available at URL https://trialsearch.who.int/; Unique Identifiers: NTR1698 and NTR1106.
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Bergan, Stein , Hesselink, Dennis A. , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lemaı̂tre, F. , Marquet, Pierre , Molinaro, Mariadelfina , Noceti, Ofelia , Pattanaik, Smita , Seger, Christoph , Shipkova, Maria , Swen, Jesse J. , Gelder, Teun van , Venkataramanan, Raman , Wieland, Eberhard , Woillard, Jean‐Baptiste , Zwart, Tom C. , Barten, M.J., Budde, Klemens , Haufroid, Vincent , Millán, Olga , Mizuno, Tomoyuki , Oellerich, Michael , Salzmann, Linda, Tönshoff, Burkhard , Schaik, Ron H. N. van , Vethe, Nils Tore , Vinks, Alexander A. , Wallemacq, Pierre, Åsberg, Anders , Langman, Loralie J., Budde, Klemens , Brunet, Merçè , Pawiński, Tomasz , Dieterlen, Maja‐Theresa , Elens, Laure , Masuda, Satohiro , Moes, Dirk Jan A. R. , Picard, Nicolas

Mayo Clinic

Therapeutic Drug Monitoring | March 12, 2021 | Volume: 43 | Issue: 2 | Pages: 150-200

10.1097/ftd.0000000000000871 | PMID 33711005 Get It

Abstract: When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and comprehensive presentation of consensus on the status for personalized treatment with MPA, this report was prepared following an initiative from members of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Topics included are the criteria for analytics, methods to estimate exposure including pharmacometrics, the potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention. For selected topics with sufficient evidence, such as the application of limited sampling strategies for MPA area under the curve, graded recommendations on target ranges are presented. To provide a comprehensive review, this report also includes updates on the status of potential biomarkers including those which may be promising but with a low level of evidence. In view of the fact that there are very few new immunosuppressive drugs under development for the transplant field, it is likely that MPA will continue to be prescribed on a large scale in the upcoming years. Discontinuation of therapy due to adverse effects is relatively common, increasing the risk for late rejections, which may contribute to graft loss. Therefore, the continued search for innovative methods to better personalize MPA dosage is warranted.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, Mercè , Gelder, Teun van , Åsberg, Anders , Haufroid, Vincent , Hesselink, Dennis A. , Langman, Loralie J., Lemaı̂tre, F. , Marquet, Pierre , Seger, Christoph , Shipkova, Maria , Vinks, Alexander A. , Wallemacq, Pierre, Wieland, Eberhard , Woillard, Jean‐Baptiste , Barten, Markus J. , Budde, Klemens , Colom, Helena , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Mathew, Binu , Millán, Olga , Mizuno, Tomoyuki , Monchaud, Caroline , Noceti, Ofelia , Picard, Nicolas , Schaik, Ron HN van , Sommerer, Claudia , Vethe, Nils Tore , Winter, Brenda C. M. de , Christians, Uwe , Bergan, Stein , Langman, Loralie, Budde, Klemens , Dieterlen, Maja‐Theresa , Elens, Laure , MacPhee, Iain A. M. , Masuda, Satohiro , Moes, Dirk Jan A. R. , Pawiński, Tomasz

Mayo Clinic

Therapeutic Drug Monitoring | April 30, 2019 | Volume: 41 | Issue: 3 | Pages: 261-307

10.1097/ftd.0000000000000640 | PMID 31045868 Get It

Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. The consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its PG and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable, the quality of evidence and the strength of recommendations were graded according to a published grading guide. After iterated editing, the final version of the complete document was approved by all authors. For each category of solid organ and stem cell transplantation, the current state of PK monitoring is discussed and the specific targets of tacrolimus trough concentrations (predose sample C 0 ) are presented for subgroups of patients along with the grading of these recommendations. In addition, tacrolimus area under the concentration–time curve determination is proposed as the best TDM option early after transplantation, at the time of immunosuppression minimization, for special populations, and specific clinical situations. For indications other than transplantation, the potentially effective tacrolimus concentrations in systemic treatment are discussed without formal grading. The importance of consistency, calibration, proficiency testing, and the requirement for standardization and need for traceability and reference materials is highlighted. The status for alternative approaches for tacrolimus TDM is presented including dried blood spots, volumetric absorptive microsampling, and the development of intracellular measurements of tacrolimus. The association between CYP3A5 genotype and tacrolimus dose requirement is consistent (Grading A I). So far, pharmacodynamic and immunologic biomarkers have not entered routine monitoring, but determination of residual nuclear factor of activated T cells–regulated gene expression supports the identification of renal transplant recipients at risk of rejection, infections, and malignancy (B II). In addition, monitoring intracellular T-cell IFN-g production can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II). Although cell-free DNA seems a promising biomarker of acute donor injury and to assess the minimally effective C 0 of tacrolimus, multicenter prospective interventional studies are required to better evaluate its clinical utility in solid organ transplantation. Population PK models including CYP3A5 and CYP3A4 genotypes will be considered to guide initial tacrolimus dosing. Future studies should investigate the clinical benefit of time-to-event models to better evaluate biomarkers as predictive of personal response, the risk of rejection, and graft outcome. The Expert Committee concludes that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade. Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacrolimus therapy and to improve long-term outcomes for treated patients.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Guchelaar, Henk‐Jan , Schwab, Matthias , Province, Michael A. , Symmans, W. Fraser , McLeod, Howard L. , Ratain, Mark J. , Zembutsu, Hitoshi , Schaik, Ron HN van , Caudle, Kelly E. , Ingle, James N. , Symmans, W Fraser , Goetz, Matthew P. , Sangkuhl, Katrin , Whirl‐Carrillo, Michelle , Gaedigk, Andrea , Klein, Teri E. , Schwab, Matthias , Province, Mike

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 31, 2018 | Volume: 103 | Issue: 5 | Pages: 770-777

10.1002/cpt.1007 | PMID 29385237 Get It

Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
Loeb, Stacy , Shin, Sanghyuk S. , Broyles, Dennis L., Wei, John T., Sanda, Martin G. , Klee, George G., Partin, Alan W. , Sokoll, Lori J. , Chan, Daniel W. , Bangma, Chris H. , Schaik, Ron H. N. van , Slawin, Kevin M., Marks, Leonard S. , Catàlona, William J. , Klee, George, Loeb, Stacy

Mayo Clinic

BJU International | October 15, 2016 | Volume: 120 | Issue: 1 | Pages: 61-68

10.1111/bju.13676 | PMID 27743489 Get It

Objective To examine the use of the Prostate Health Index ( PHI ) as a continuous variable in multivariable risk assessment for aggressive prostate cancer in a large multicentre US study. Materials and Methods The study population included 728 men, with prostate‐specific antigen ( PSA ) levels of 2–10 ng/ mL and a negative digital rectal examination, enrolled in a prospective, multi‐site early detection trial. The primary endpoint was aggressive prostate cancer, defined as biopsy Gleason score ≥7. First, we evaluated whether the addition of PHI improves the performance of currently available risk calculators (the Prostate Cancer Prevention Trial [ PCPT ] and European Randomised Study of Screening for Prostate Cancer [ ERSPC ] risk calculators). We also designed and internally validated a new PHI ‐based multivariable predictive model, and created a nomogram. Results Of 728 men undergoing biopsy, 118 (16.2%) had aggressive prostate cancer. The PHI predicted the risk of aggressive prostate cancer across the spectrum of values. Adding PHI significantly improved the predictive accuracy of the PCPT and ERSPC risk calculators for aggressive disease. A new model was created using age, previous biopsy, prostate volume, PSA and PHI , with an area under the curve of 0.746. The bootstrap‐corrected model showed good calibration with observed risk for aggressive prostate cancer and had net benefit on decision‐curve analysis. Conclusion Using PHI as part of multivariable risk assessment leads to a significant improvement in the detection of aggressive prostate cancer, potentially reducing harms from unnecessary prostate biopsy and overdiagnosis.
Minimum Information Required for a DMET Experiment Reporting
Kumuthini, Judit , Mbiyavanga, Mamana , Chimusa, Emile R. , Pathak, Jyotishman , Somervuo, Panu , Schaik, Ron HN van , Mizzi, Clint, Kalideen, Kusha, Ramesar, Raj , Maçek, Milan , Squassina, Alessio , Dolžan, Vita , Patrinos, George P. , Squassina, Alessio

Mayo Clinic

Pharmacogenomics | August 22, 2016 | Volume: 17 | Issue: 14 | Pages: 1533-1545

10.2217/pgs-2016-0015 | PMID 27548815 Get It

The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Sanda, Martin G. , Broyles, Dennis L., Shin, Sanghyuk S. , Bangma, Chris H. , Wei, John T., Partin, Alan W. , Klee, George G., Slawin, Kevin M., Marks, Leonard S. , Schaik, Ron H. N. van , Chan, Daniel W. , Sokoll, Lori J. , Cruz, Amabelle B., Mizrahi, Isaac, Catàlona, William J. , Loeb, Stacy

Mayo Clinic

Journal of Urology | November 17, 2014 | Volume: 193 | Issue: 4 | Pages: 1163-1169

10.1016/j.juro.2014.10.121 | PMID 25463993 Get It